These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34399406)

  • 1. BBCIC Research Network Analysis of First-Cycle Prophylactic G-CSF Use in Patients Treated With High-Neutropenia Risk Chemotherapy.
    Pawloski PA; McDermott CL; Marshall JH; Pindolia V; Lockhart CM; Panozzo CA; Brown JS; Eichelberger B
    J Natl Compr Canc Netw; 2021 Aug; ():. PubMed ID: 34399406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harnessing the Biologics and Biosimilars Collective Intelligence Consortium to Evaluate Patterns of Care.
    McMahill-Walraven CN; Kent DJ; Panozzo CA; Pawloski PA; Haynes K; Marshall J; Brown J; Eichelberger B; Lockhart CM
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1156-1161. PubMed ID: 31397619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
    Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
    Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
    Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
    Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
    J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
    Mahtani R; Crawford J; Flannery SM; Lawrence T; Schenfeld J; Gawade PL
    BMC Cancer; 2021 May; 21(1):621. PubMed ID: 34044798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019.
    Wang CY; Heldermon CD; Vouri SM; Park H; Wheeler SE; Ramnaraign BH; Dang NH; Brown JD
    JAMA Netw Open; 2021 Nov; 4(11):e2133474. PubMed ID: 34812849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study.
    Wang CY; Vouri SM; Park H; Heldermon CD; Brown JD
    J Manag Care Spec Pharm; 2023 Feb; 29(2):119-127. PubMed ID: 36705287
    [No Abstract]   [Full Text] [Related]  

  • 9. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
    Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
    Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risks and consequences of travel burden on prophylactic granulocyte colony-stimulating factor administration and incidence of febrile neutropenia in an aged Medicare population.
    Stephens JM; Bensink M; Bowers C; Hollenbeak CS
    Curr Med Res Opin; 2019 Feb; 35(2):229-240. PubMed ID: 29661043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices.
    Morrison VA; Wong M; Hershman D; Campos LT; Ding B; Malin J
    J Manag Care Pharm; 2007 May; 13(4):337-48. PubMed ID: 17506600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world cost-effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate/high risk of febrile neutropenia.
    Cornes P; Kelton J; Liu R; Zaidi O; Stephens J; Yang J
    Future Oncol; 2022 Mar; ():. PubMed ID: 35354304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.
    Botteri E; Krendyukov A; Curigliano G
    Eur J Cancer; 2018 Jan; 89():49-55. PubMed ID: 29227817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.
    Pfeil AM; Allcott K; Pettengell R; von Minckwitz G; Schwenkglenks M; Szabo Z
    Support Care Cancer; 2015 Feb; 23(2):525-45. PubMed ID: 25284721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance.
    Zhang J; Sridhar G; Barr CE; Eichelberger B; Lockhart CM; Marshall J; Clewell J; Accortt NA; Curtis JR; Holmes C; McMahill-Walraven CN; Brown JS; Haynes K
    J Manag Care Spec Pharm; 2020 Apr; 26(4):417-490. PubMed ID: 32223608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription patterns of granulocyte colony-stimulating factors in patients with breast cancer: A real-world study.
    Hsu SW; Chiang SC; Hsu JC; Ko Y
    PLoS One; 2023; 18(7):e0288642. PubMed ID: 37459309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients.
    Guariglia R; Martorelli MC; Lerose R; Telesca D; Milella MR; Musto P
    Biologics; 2016; 10():1-8. PubMed ID: 26858523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom.
    Whyte S; Cooper KL; Stevenson MD; Madan J; Akehurst R
    Value Health; 2011 Jun; 14(4):465-74. PubMed ID: 21669371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.
    Cooper KL; Madan J; Whyte S; Stevenson MD; Akehurst RL
    BMC Cancer; 2011 Sep; 11():404. PubMed ID: 21943360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.